ACHN @ Canaccord Adams (8/11/09)
There were a few key notes from this conference as follows:
1. ACH-1625 - ACHN is finishing the final cohort of the Phase 1a single ascending dose trial in healthy patients and the compound is still behaving in-line with its pre-clinical profile. The multiple ascending dose portion of the trial will commence shortly and should be complete by the end of 3Q09.
2. ACHN expects to complete the Phase 1b portion of the trial in HCV-infected patients by the end of 1Q10 and to initiate Phase 2 during 2Q10.
3. ACHN expects the interval between proof-of-concept for ACH-1625 (Phase 1b data), assuming success of course, and a partner to be "brief."
4. ACH-1095 - We finally got some more specific color on the tox signal seen with this compound during pre-clinical testing. Apparently, the drug was clean in monkeys and dogs but there were "some signals of a cardiac nature" seen in rats at doses far greater than what would be tested in humans.
5. As previously noted, ACHN is working on a separate class of HCV compounds outside of PIs and the NS4A antagonist program that they will more specifically disclose in the coming months. However, the company did say that the primary focus of this new class of compounds is on "issues of resistance and overall potency."
Market Data 
Markets 
AI
